DNA Plasmid Manufacturing Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product Type, Application, End User and Geography

Description

List of Tables

The DNA plasmid Manufacturing Market is expected to reach US$ 2,648.36 Mn by 2031 from US$ 686.38 Mn in 2024; the market is estimated to grow at a CAGR of 21.4% during 2025-2031. Major factors driving the market growth include increasing plasmid developments for gene therapy and growing research on DNA plasmid vaccine development. However, high manufacturing costs among the market deterrents.

The rise in the prevalence of genetic diseases, orphan diseases, and other cancers has accelerated the advancement of gene therapy technologies, which are based largely on plasmid DNA as the fundamental element. Plasmid DNA helps introduce genetic material into patients' cells. It acts as a non-viral vector to deliver therapeutic genes that can fix or replace faulty genes. Unlike viral vectors, plasmids are safer, easier to produce, and cheaper, making them popular in gene therapy.

As gene therapies transition from preclinical development to clinical trials and commercial launch, the demand for substantial quantities of high-purity, GMP-grade plasmid DNA has escalated significantly. In March 2023, Charles River Laboratories International, Inc. announced the launch of its off-the-shelf pHelper (Helper Plasmid) offering, which is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.

Growing partnerships between companies to meet the quality and regulatory demands of gene therapy pipelines. In 2022, Myrtelle and Forge Biologics announced a viral vector and plasmid DNA cGMP manufacturing partnership. Forge will provide research-grade and GMP-Pathway plasmid manufacturing services as well as cGMP adeno-associated viral (AAV) process development and scale-up manufacturing services for Myrtelle's program, Myr-201 (novel gene therapy for monogenic hearing loss).

Governments and regulatory agencies are also helping to drive this trend with expedited approvals for gene therapy products and national biotech infrastructure investment. VGXI, Inc. recently completed a successful FDA inspection at its GMP facility in Conroe, Texas. This inspection led to the approval of a client's Biologics License Application (BLA). VGXI's achievement reinforces its credibility as a plasmid DNA manufacturing leader as well as underscores its importance in enabling commercial-stage gene therapies, DNA vaccines, and RNA-based medicines.

The DNA plasmid market is transforming from a specialized research supply chain to an essential backbone of contemporary therapeutic development. Therefore, the increasing development of plasmid for gene therapy drives the DNA plasmid manufacturing market.

The comparative company analysis evaluates and categorizes the DNA plasmid Manufacturing Market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global DNA plasmid Manufacturing Market. The key market players are WuXi Biologics Inc, Charles River Laboratories International Inc, Catalent Inc, Thermo Fisher Scientific Inc., AGC Biologics AS, Takara Bio Inc, SK pharmteco Inc, Sartorius, Creative Biogene, GenScript Biotech Corporation

The DNA plasmid Manufacturing Market, based on product type, is divided into GMP Grade and R&D grade. The GMP Grade segment held the largest share of the DNA plasmid Manufacturing Market in 2024, and it is expected to register the highest CAGR during 2024-2031. Based on Application, the DNA plasmid Manufacturing Market is segmented into Cell and Gene Therapy, DNA Vaccines, Immunotherapy, and Others. In 2024, the cell and gene therapy segment held the largest share of the market. Based on end user, the DNA plasmid Manufacturing Market is segmented into Pharmaceutical and Biotechnology Companies, CROs and CDMOs and Others. In 2024, the Pharmaceutical and Biotechnology Companies segment held the largest share of the market.

Various organic and inorganic strategies are adopted by companies operating in the DNA plasmid Manufacturing Market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the DNA plasmid Manufacturing Market are listed below.

In March 2025, WuXi Biologics Launched EffiX Microbial Expression Platform to Boost Recombinant Protein and Plasmid DNA Production. EffiX is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for developing and manufacturing non-monoclonal antibody (non-mAb) recombinant proteins and plasmid DNA for clients across the globe. EffiX delivers high-yield production across multiple modalities, achieving titers of over 15 g/L for non-mAb recombinant proteins and over 1 g/L for plasmid DNA.

Product Code: TIPRE00021640

1. Introduction

1.1 Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Analyst Market Outlook

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
3.3 Assumptions and Limitations

4. DNA Plasmid Manufacturing Market Landscape

4.1 PEST Analysis

5. DNA Plasmid Manufacturing Market - Key Market Dynamics

5.1 DNA Plasmid Manufacturing Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Increasing Plasmid Developments for Gene Therapy
- 5.2.2 Growing Research on DNA Plasmid Vaccine Development
5.3 Market Restraints
- 5.3.1 High Manufacturing Costs
5.4 Market Opportunities
- 5.4.1 Expansion of Contract Development and Manufacturing Organizations (CDMOs)
5.5 Future Trends
- 5.5.1 Integration of Digital Technologies in Plasmid DNA Manufacturing
5.6 Impact of Drivers and Restraints:

6. DNA Plasmid Manufacturing Market - Global Market Analysis

6.1 DNA Plasmid Manufacturing Market Revenue (US$ Million), 2021-2031
6.2 DNA Plasmid Manufacturing Market Forecast Analysis

7. DNA Plasmid Manufacturing Market Analysis - by Product Type

7.1 GMP Grade
- 7.1.1 Overview
- 7.1.2 GMP Grade: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
7.2 R&D grade
- 7.2.1 Overview
- 7.2.2 R&D grade: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)

8. DNA Plasmid Manufacturing Market Analysis - by Application

8.1 Cell and Gene Therapy
- 8.1.1 Overview
- 8.1.2 Cell and Gene Therapy: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8.2 DNA Vaccines
- 8.2.1 Overview
- 8.2.2 DNA Vaccines: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Immunotherapy
- 8.3.1 Overview
- 8.3.2 Immunotherapy: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Others
- 8.4.1 Overview
- 8.4.2 Others: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)

9. DNA Plasmid Manufacturing Market Analysis - by End User

9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Overview
- 9.1.2 Pharmaceutical and Biotechnology Companies: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9.2 CROs and CDMOs
- 9.2.1 Overview
- 9.2.2 CROs and CDMOs: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: DNA Plasmid Manufacturing Market - Revenue and Forecast to 2031 (US$ Million)

10. DNA Plasmid Manufacturing Market - Geographical Analysis

10.1 Overview
10.2 North America
- 10.2.1 North America DNA Plasmid Manufacturing Market Overview
- 10.2.2 North America: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.2.3 North America: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.2.3.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.2.4 North America: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.2.4.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.2.5 North America: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.2.5.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.2.6 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.1 North America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.2.6.2 United States: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.2.1 United States: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.2.6.2.2 United States: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.2.6.2.3 United States: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.2.6.3 Canada: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.3.1 Canada: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.2.6.3.2 Canada: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.2.6.3.3 Canada: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.2.6.4 Mexico: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.2.6.4.1 Mexico: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.2.6.4.2 Mexico: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.2.6.4.3 Mexico: DNA Plasmid Manufacturing Market Breakdown, by End User
10.3 Europe
- 10.3.1 Europe DNA Plasmid Manufacturing Market Overview
- 10.3.2 Europe: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.3.3 Europe: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.3.3.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.3.4 Europe: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.3.4.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.3.5 Europe: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.5.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.3.6 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.1 Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.3.6.2 Germany: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.2.1 Germany: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.2.2 Germany: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.2.3 Germany: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.3 United Kingdom: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.3.1 United Kingdom: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.3.2 United Kingdom: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.3.3 United Kingdom: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.4 France: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.4.1 France: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.4.2 France: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.4.3 France: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.5 Italy: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.5.1 Italy: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.5.2 Italy: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.5.3 Italy: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.6 Spain: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.6.1 Spain: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.6.2 Spain: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.6.3 Spain: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.3.6.7 Rest of Europe: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.3.6.7.1 Rest of Europe: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.3.6.7.2 Rest of Europe: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.3.6.7.3 Rest of Europe: DNA Plasmid Manufacturing Market Breakdown, by End User
10.4 Asia Pacific
- 10.4.1 Asia Pacific DNA Plasmid Manufacturing Market Overview
- 10.4.2 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.4.3 Asia Pacific: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.4.3.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.4.4 Asia Pacific: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.4.4.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.4.5 Asia Pacific: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.5.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.4.6 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.1 Asia Pacific: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.4.6.2 China: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.2.1 China: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.2.2 China: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.2.3 China: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.3 Japan: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.3.1 Japan: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.3.2 Japan: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.3.3 Japan: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.4 India: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.4.1 India: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.4.2 India: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.4.3 India: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.5 Australia: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.5.1 Australia: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.5.2 Australia: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.5.3 Australia: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.6 South Korea: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.6.1 South Korea: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.6.2 South Korea: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.6.3 South Korea: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.4.6.7 Rest of APAC: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.4.6.7.1 Rest of APAC: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.4.6.7.2 Rest of APAC: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.4.6.7.3 Rest of APAC: DNA Plasmid Manufacturing Market Breakdown, by End User
10.5 Middle East and Africa
- 10.5.1 Middle East and Africa DNA Plasmid Manufacturing Market Overview
- 10.5.2 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.5.3 Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.5.3.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.5.4 Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.5.4.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.5.5 Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.5.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.5.6 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.1 Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.5.6.2 Saudi Arabia: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.2.1 Saudi Arabia: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.2.2 Saudi Arabia: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.2.3 Saudi Arabia: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.6.3 South Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.3.1 South Africa: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.3.2 South Africa: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.3.3 South Africa: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.6.4 United Arab Emirates: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.4.1 United Arab Emirates: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.4.2 United Arab Emirates: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.4.3 United Arab Emirates: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.5.6.5 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.5.6.5.1 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.5.6.5.2 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.5.6.5.3 Rest of Middle East and Africa: DNA Plasmid Manufacturing Market Breakdown, by End User
10.6 South and Central America
- 10.6.1 South and Central America DNA Plasmid Manufacturing Market Overview
- 10.6.2 South and Central America: DNA Plasmid Manufacturing Market - Revenue, 2021-2031 (US$ Million)
- 10.6.3 South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Product Type
  - 10.6.3.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Product Type
- 10.6.4 South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Application
  - 10.6.4.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Application
- 10.6.5 South and Central America: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.6.5.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by End User
- 10.6.6 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.1 South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast Analysis - by Country
  - 10.6.6.2 Brazil: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.2.1 Brazil: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.6.6.2.2 Brazil: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.6.6.2.3 Brazil: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.6.6.3 Argentina: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.3.1 Argentina: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.6.6.3.2 Argentina: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.6.6.3.3 Argentina: DNA Plasmid Manufacturing Market Breakdown, by End User
  - 10.6.6.4 Rest of South and Central America: DNA Plasmid Manufacturing Market - Revenue and Forecast, 2021-2031 (US$ Million)
    - 10.6.6.4.1 Rest of South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Product Type
    - 10.6.6.4.2 Rest of South and Central America: DNA Plasmid Manufacturing Market Breakdown, by Application
    - 10.6.6.4.3 Rest of South and Central America: DNA Plasmid Manufacturing Market Breakdown, by End User

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Market Share Analysis, 2024

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies in the Nigeria Infectious Disease In-Vitro Diagnostics Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Sartorius AG
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 WuXi Biologics Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Charles River Laboratories International Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Catalent Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Thermo Fisher Scientific Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 AGC Biologics AS
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Takara Bio Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
13.8 Creative Biogene
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 SK Pharmteco Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 GenScript Biotech Corporation
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms